Patents by Inventor Michael Sturgess

Michael Sturgess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 8691864
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 8, 2014
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20120295946
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: July 26, 2012
    Publication date: November 22, 2012
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 8258172
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: September 4, 2012
    Assignees: Raptor Pharmaceutical Corp, National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20110021594
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: July 22, 2010
    Publication date: January 27, 2011
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 7786162
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: August 31, 2010
    Assignees: Raptor Pharmaceutical Corp., National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20090131501
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: January 21, 2009
    Publication date: May 21, 2009
    Applicants: TorreyPines Therapeutics, National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Screening Method for Dnak Inhibitors
    Publication number: 20080268488
    Abstract: Screening methods for identification of inhibitors of DnaK activity are provided. Such inhibitors have utility as antibacterial agents.
    Type: Application
    Filed: November 6, 2006
    Publication date: October 30, 2008
    Inventor: Michael A. Sturgess
  • Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
    Publication number: 20070099201
    Abstract: The invention features methods for detecting and quantifying the binding or inhibition of binding of species to biopolymers, e.g., nucleic acids. The invention is based on the use of probes that have magnetic relaxation properties that are affected by the presence of paramagnetic metal ions, e.g., Mn2+. Any class of biopolymer that binds metal ions at its active site or uses metal ion cofactors can be studied using these methods.
    Type: Application
    Filed: May 1, 2006
    Publication date: May 3, 2007
    Inventors: Jack Summers, Michael Sturgess, John Shimko
  • Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
    Patent number: 7153882
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: December 26, 2006
    Assignees: The United States of America as represented by the Department of Health and Human Services, The National Institutes of Health and Axonyx, Inc.
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Timothy T. Sencrant, Tada Utsuki, Donald Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Novel combinations of DnaK inhibitors with known antibacterial agents
    Publication number: 20060287238
    Abstract: Compositions, methods and kits are provided comprising (a) a therapeutically effective amount of a DnaK inhibitor; and (b) a therapeutically effective amount of a known antibacterial agent. Such compositions, methods and kits are useful in the treatment of various bacterial infections.
    Type: Application
    Filed: June 17, 2005
    Publication date: December 21, 2006
    Inventors: Michael Sturgess, Kenneth Kovan
  • Agents useful for reducing amylioid precursor protein and treating dementia and methods of use thereof
    Publication number: 20060270729
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: June 20, 2006
    Publication date: November 30, 2006
    Inventors: Nigel Greig, Karen Shaw, Qiang-Sheng Yu, Harold Holloway, Tada Utsuki, Timothy Soncrant, Donald Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
    Patent number: 7037660
    Abstract: The invention features methods for detecting and quantifying the binding or inhibition of binding of species to biopolymers, e.g., nucleic acids. The invention is based on the use of probes that have magnetic relaxation properties that are affected by the presence of paramagnetic metal ions, e.g., Mn2+. Any class of biopolymer that binds metal ions at its active site or uses metal ion cofactors can be studied using these methods.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: May 2, 2006
    Assignee: Message Pharmaceuticals
    Inventors: Jack Summers, Michael Sturgess, John Shimko
  • Inhibitors of RNase P proteins as antibacterial compounds
    Patent number: 7001924
    Abstract: The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds. Exemplary compounds are compounds of formula I: Y—(NR?)k—U1—(NR?)I—A—(NR1)m—U2—(NR2)n—Z??I with substituents as described herein.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: February 21, 2006
    Assignee: Message Pharmaceuticals
    Inventors: Tony Giordano, Michael A. Sturgess, Samala J. Rao
  • Inhibitors of RNase P proteins as antibacterial compounds
    Publication number: 20050187409
    Abstract: The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones and benzoic acid compounds.
    Type: Application
    Filed: October 21, 2004
    Publication date: August 25, 2005
    Inventors: Gordon Powers, Michael Sturgess
  • Small molecule inhibitors of secretion of proteins encoded by ARE-mRNAs
    Patent number: 6872850
    Abstract: The invention features compounds that inhibit secretion of a protein encoded by an ARE-mRNA or that modulate regulation of an ARE-mRNA. These compounds are useful for the treatment or prevention of conditions involving proteins encoded by ARE-mRNAs, such as TNF?.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: March 29, 2005
    Assignee: Message Pharmaceuticals
    Inventors: Tony Giordano, Michael A. Sturgess
  • Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
    Publication number: 20040138282
    Abstract: The present invention provides compounds and methods of administering compounds to a subject taht can reduce &bgr;APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce &bgr;APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease &bgr;APP production.
    Type: Application
    Filed: February 6, 2004
    Publication date: July 15, 2004
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Timothy T. Sencrant, Tada Utsuki, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Small molecule inhibitors of secretion of proteins encoded by ARE-mRNAs
    Publication number: 20030199453
    Abstract: The invention features compounds that inhibit secretion of a protein encoded by an ARE-mRNA or that modulate regulation of an ARE-mRNA. These compounds are useful for the treatment or prevention of conditions involving proteins encoded by ARE-mRNAs, such as TNF&agr;.
    Type: Application
    Filed: April 8, 2002
    Publication date: October 23, 2003
    Inventors: Tony Giordano, Michael A. Sturgess
  • Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
    Publication number: 20030148343
    Abstract: The invention features methods for detecting and quantifying the binding or inhibition of binding of species to biopolymers, e.g., nucleic acids. The invention is based on the use of probes that have magnetic relaxation properties that are affected by the presence of paramagnetic metal ions, e.g., Mn2+. Any class of biopolymer that binds metal ions at its active site or uses metal ion cofactors can be studied using these methods.
    Type: Application
    Filed: November 6, 2002
    Publication date: August 7, 2003
    Inventors: Jack Summers, Michael Sturgess, John Shimko
  • Inhibitors of RNase P proteins as antibacterial compounds
    Publication number: 20030134904
    Abstract: The present invention features compounds useful for inhibiting RNase P activity. These compounds can be used as therapeutics for treating or preventing a variety of bacterial infections. The compounds belong to several classes including mono- and bis-guanylhydrazones, guanylhydrazone mimetics, and benzothiazolium compounds.
    Type: Application
    Filed: September 23, 2002
    Publication date: July 17, 2003
    Inventors: Tony Giordano, Michael A. Sturgess, Samala J. Rao